Esketamine drug is employed within the treatment of restrictive depression
in adults. In 1997 Esketamine is introduced in medical use and now in March
5th, 2019 it's approved by FDA for the treatment of depression in adults by
nasal route. Oneamong good advantage of Nasal Spray is that it'll act faster
and potentially help those patients which experience suicidal thoughts more
quickly. it's the non-competitive N-methyl-D-aspartate (NMDA) receptor
antagonist and up to some extent it'll also act on dopamine reuptake inhibitor
but don't interact with sigma receptor as like ketamine drug. it's a sort of
ketamine drug which is approved by FDA in 1970 which having two chemical
forms R and S and Esketamine contain on of it and that i .e. S form.
Share this article
Journal of Formulation Science & Bioavailability received 23 citations as per Google Scholar report
